Natasa Chatziprimou’s Post

Keir Milburn from Abundance (UK) proposes public-common partnership to build an alternative pharmaceutical infrastructure. 🏥  “It is Important is to have transparent finances, re-invested into the industry and not in the pockets of people who are already rich.”  Milburn makes clear that to move away from the current model, we will need a strategy. Now it is Big Pharma who has the resources and they put extra pressure by claiming that there is no alternative. But one by one, we can build a public-common network and we can achieve a democratic way of organizing the medicines production by putting our own demands. 🏥🔥 #Publicpharmaeurope

Tune in to the video and explore the perspectives shared by Vassilis Kontozamanis, Adviser to the Prime Minister, Greece, at Delphi Economic Forum, on the panel “Developing Collaborative Strategies to foster a sustainable environment for pharmaceutical innovation”. #delphiforum #pifgreece #innovation #pharma

📢 Competition partner and life sciences expert Michael Clancy will speak at the Informa Connect CompLaw Pharma Conference in Brussels on 3 December. Michael’s session will cover:   ➡ An update on recent cases addressing parallel trade (including the impact of the Mondelez decision) ➡Practical considerations for pharma distribution strategies ➡Security of supply considerations   Michael will join Cristiane Ferreira Claerhout (Alnylam Pharmaceuticals) and Dr. Despoina Samara - Babinioti (GSK) on this expert panel.   If you’re interested in joining, you can get 30% off your ticket and see the full agenda below: https://bit.ly/3Uuhwyn   #VBB #CompLawPharma #CompetitionLaw #PharmaDistribution

Despite its role in improving people’s lives, the pharma sector hasn’t always put the patient at the center of how it operates. In this article we explain why a patient centric approach in pharma is now vital: https://lnkd.in/gPH7S8iA #pharma #patientcentricity #innovation

At TAXIS Pharmaceuticals, Inc., our mission is simple: to fight antimicrobial resistance and save lives. 🛡️ The time to act is now!💥 Antimicrobial resistance is a global crisis that requires immediate, coordinated efforts from governments, healthcare providers, researchers, and the pharmaceutical industry. By investing in cutting-edge solutions and fostering worldwide collaboration, we can make a difference. 🌎 We’re proud that the World Health Organization recognized our most advanced investigational drug candidate, TXA709, as one of only two antibacterials (out of 26) to meet all innovation criteria in research. 🧪 Learn more about how TAXIS Pharmaceuticals, Inc. is leading the charge. https://bit.ly/3XzqcFW. #lifesciences #healthinnovation #research #innovation #medtech #drugdiscovery #biotech #partnerships #biopharma #healthtech #healthcare #investors #invest #startups #pharma #medicine

LogiPharma Celebrates 25 Years in 2025 with Strategic Return to Lyon LogiPharma is celebrating its 25th anniversary in 2025 by returning to Lyon, reaffirming its position as a key European Pharmaceutical Manufacturer. Over the past quarter-century, LogiPharma has expanded into over 15 countries, developed more than 50 pharmaceutical products, and exceeded sustainability targets. The company's move back to Lyon aims to create local jobs, collaborate with research institutions, and invest in community health initiatives. Future plans include enhancing R&D facilities, adopting new pharmaceutical technologies, and expanding its European footprint. This milestone highlights LogiPharma's commitment to innovation, excellence, and its role in advancing the pharmaceutical industry. Read more: https://lnkd.in/gVwTuwqN #ai #sustainability #esg #environmentalengineering #environmental #carbon #decarbonization #LogiPharma #PharmaceuticalIndustry #Lyon #EuropeanManufacturer #25Years #AIGC

Contract Development and Manufacturing Organisations (CDMOs) help Pharmaceutical and MedTech companies efficiently develop, manufacture, and bring products to market. For astute players who can navigate its landscape, the M&A market presents considerable growth opportunities. Key factors fuelling the rise of the CDMO market include: - The increasing outsourcing of services by Pharma and MedTech Original Equipment Manufacturers - Service expansion via new innovative therapies and medical technology - Consolidation opportunities via a high number of specialised SMEs - An aging population demanding personalised medicine - Regulatory complexity providing greater tailwinds Our latest insights paper explores these themes, highlighting key transactions that are shaping the field, presenting selected case studies, and providing a broader outlook for the sector. Read our latest paper here: https://okt.to/AivL75 Authors: Al-Munther Sultan, Jane Hartley, Claire Edwards, Chris Savidge, Steven Young #Health #CDMO #Contract #Development #Pharmaceutical #Pharma #MedTech #Manufacturing #OEMs #MergersandAcquisitions #AMon

“𝐌𝐞𝐞𝐭 𝐔𝐬 𝐚𝐭 𝐭𝐡𝐞 𝐏𝐡𝐚𝐫𝐦𝐚 𝐂𝐈 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 & 𝐄𝐱𝐡𝐢𝐛𝐢𝐭𝐢𝐨𝐧!”   At AdametNext, we specialize in "𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐑𝐞𝐚𝐝𝐢𝐧𝐞𝐬𝐬 𝐚𝐧𝐝 𝐌𝐨𝐧𝐢𝐭𝐨𝐫𝐢𝐧𝐠," essential for staying ahead in today's dynamic pharmaceutical landscape.   Learn about our 𝐏𝐇𝐀𝐑𝐌𝐀 𝐂𝐈 𝐰𝐢𝐭𝐡 𝐈𝐍𝐒𝐈𝐃𝐄-𝐎𝐔𝐓 𝐁𝐔𝐒𝐈𝐍𝐄𝐒𝐒 𝐒𝐓𝐑𝐀𝐓𝐄𝐆𝐘 from our industry experts - Virendra Kumar and Amit Pharande, who will provide strategic insights to navigate challenges and seize opportunities in pharma.   📅 Save the Date: September 25th & 26th, 2024  📍 Newark, NJ   Don’t miss out on this exclusive opportunity to connect with us at Pharma CI and explore how our expertise can drive your business forward.   #CompetitiveReadiness #MarketIntelligence #PharmaCI #Newark #AdametNext

Are We Too Reliant on Big Pharma? A Growing Concern As discussions around corporate influence in healthcare intensify, one question looms large: Are we too reliant on Big Pharma? With figures like Robert F. Kennedy Jr. echoing sentiments that resonate with both critics and supporters of various political ideologies, it's clear that skepticism towards pharmaceutical companies is becoming a unifying theme across the spectrum. #Pharma #Reliant #Big #Concern #Growing https://lnkd.in/dScH8y3t

GLP-1 drugs are transforming the healthcare industry. While the impact on the pharmaceutical industry is well analyzed, effects on the MedTech industry remain mostly unclear. To resolve this issue, Strategy& is diving deeper into the MedTech industry. As part of the initiative we are conducting a survey to gather insights from industry experts. Here your help is required. Please participate in our survey. By participating you ... ... contribute to key findings on the development of the MedTech industry ... gain early access to study results ... help enabling the future of health The survey only consists of 7 questions. It takes less than 3 minutes to answer them. Click here to participate: https://lnkd.in/ezsDqfWP Thank you for your support 🙏 Let's enable the future of health together 🚀 #MedTech #FutureofHealth #GLP-1 Dr. Thomas Solbach, Dr. Jens Neumann, Oliver R. Dolny, Christian Kaspar, Fabian Ahrens, Jonathan Müller, Fritz Heese, Christelle Azar, Anne Scheidt, Dr. Christoph S Gross, Iryna (Stadnyk) Scheurlen, Kariem Schlieper, Jonas Grefe